CRNX Stock Analysis: Crinetics Pharmaceuticals | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.920m USD | 12M Return: 207.1% | US22663K1079 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 272M
Qual. Beats: 1
Rev. Trend: 48.4%
Qual. Beats: 3
Warnings
Tailwinds
Seasonality 8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Crinetics Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral, nonpeptide therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead candidate, Paltusotine, is an oral selective somatostatin receptor type 2 (SST2) agonist currently in Phase 3 development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. As a clinical-stage company with no approved products, Crinetics has not yet generated product revenue and depends on capital markets and partnerships to fund its research and development activities.
Beyond Paltusotine, the companys pipeline includes Atumelnant, an oral ACTH receptor antagonist that has completed a Phase 1 study for conditions such as congenital adrenal hyperplasia and Cushings disease, as well as earlier-stage programs targeting parathyroid hormone (PTH) receptor antagonists for hyperparathyroidism, thyroid-stimulating hormone receptor antagonists for Graves disease and thyroid eye disease, an SST3 agonist for polycystic kidney disease, and oral nonpeptide GLP-1 and GIP candidates for obesity. The pipeline focus on rare (orphan) endocrine indications positions the company to potentially benefit from regulatory pathways such as FDA orphan drug designation, which can offer extended market exclusivity for approved therapies.
Crinetics has entered into collaboration and licensing agreements with Sanwa Kagaku Kenkyusho for the development and commercialization of Paltusotine in Japan and with Cellular Longevity for CRN01941, a somatostatin receptor type 2 agonist. The company was incorporated in 2008, is headquartered in San Diego, California, and trades on the Nasdaq under the ticker CRNX.
- Paltusotine Phase 3 acromegaly data readout approaches
- FDA approval timeline for Paltusotine nears
- Cash burn raises equity offering dilution risk
| Net Income: -501.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -8.45 > 1.0 |
| NWC/Revenue: 2.76k% < 20% (prev 82.5k%; Δ -79.8k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -422.5m > Net Income -501.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 15.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (105.6m) vs 12m ago 12.55% < -2% |
| Gross Margin: -114.3% > 18% (prev -9.20k%; Δ 9.08k% > 0.5%) |
| Asset Turnover: 3.23% > 50% (prev 0.11%; Δ 3.12% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 1.24b - Total Current Liabilities 79.9m) / Total Assets 1.32b |
| B: -1.26 (Retained Earnings -1.67b / Total Assets 1.32b) |
| C: -0.39 (EBIT TTM -513.0m / Avg Total Assets 1.31b) |
| D: 9.17 (Book Value of Equity 1.19b / Total Liabilities 129.9m) |
| Altman-Z'' = 8.66 = AAA |
| DSRI: 0.10 (Receivables 12.0m/7.31m, Revenue 42.2m/1.39m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 1.57 (AQ_t 0.02 / AQ_t-1 0.01) |
| SGI: 30.28 (Revenue 42.2m / 1.39m) |
| TATA: -0.06 (NI -501.6m - CFO -422.5m) / TA 1.32b) |
| Beneish M = 17.56 (Cap -4..+1) = D |
As of August 10, 2026, the stock is trading at USD 84.08 with a total of 1,889,803 shares traded. Over the past week, the price has changed by +0.67%, over one month by +0.55%, over three months by +130.04% and over the past year by +207.09%.
Current recommended Stop Loss: 82.80 (which is 1.5% or 1.2 ATR below the current price).
Crinetics Pharmaceuticals has received a consensus analysts rating of 4.59. Therefore, it is recommended to buy CRNX.
- StrongBuy: 11
- Buy: 5
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 85.5 | 1.7% |
P/S = 211.6065
P/B = 7.491
Revenue TTM = 42.2m USD
EBIT TTM = -513.0m USD
EBITDA TTM = -508.8m USD
Long Term Debt = 40.6m USD (estimated: total debt 47.2m - short term 6.58m)
Short Term Debt = 6.58m USD (from shortTermDebt, last quarter)
Debt = 47.2m USD (from shortLongTermDebtTotal, last quarter) (leases 47.2m already included)
Net Debt = -1.16b USD (calculated: Debt 47.2m - CCE 1.21b)
Enterprise Value = 7.76b USD (8.92b + Debt 47.2m - CCE 1.21b)
Interest Coverage Ratio = unknown (Ebit TTM -513.0m / Interest Expense TTM 0.0)
EV/FCF = -18.26x (Enterprise Value 7.76b / FCF TTM -425.2m)
FCF Yield = -5.48% (FCF TTM -425.2m / Enterprise Value 7.76b)
FCF Margin = -1.01k% (FCF TTM -425.2m / Revenue TTM 42.2m)
Net Margin = -1.19k% (Net Income TTM -501.6m / Revenue TTM 42.2m)
Gross Margin = -114.3% ((Revenue TTM 42.2m - Cost of Revenue TTM 90.4m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 5.87 (Enterprise Value 7.76b / Total Assets 1.32b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 47.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -405.3m (EBIT -513.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.57 (Total Current Assets 1.24b / Total Current Liabilities 79.9m)
Debt / Equity = 0.04 (Debt 47.2m / totalStockholderEquity, last quarter 1.19b)
Debt / EBITDA = 2.28 (negative EBITDA) (Net Debt -1.16b / EBITDA -508.8m)
Debt / FCF = 2.72 (negative FCF - burning cash) (Net Debt -1.16b / FCF TTM -425.2m)
Total Stockholder Equity = 1.13b (last 4 quarters mean from totalStockholderEquity)
RoA = -38.42% (Net Income -501.6m / Total Assets 1.32b)
RoE = -44.22% (Net Income TTM -501.6m / Total Stockholder Equity 1.13b)
RoCE = -43.67% (EBIT -513.0m / Capital Employed (Equity 1.13b + L.T.Debt 40.6m))
RoIC = -32.52% (negative operating profit) (NOPAT -405.3m / Invested Capital 1.25b)
WACC = 8.92% (E(8.92b)/V(8.97b) * Re(8.97%) + D(47.2m)/V(8.97b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.07 | Cagr: 18.33%
[DCF] Fair Price = unknown (Cash Flow -425.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.32 | # QB: 1
Revenue Correlation: 48.44 | Revenue CAGR: 96.30% | SUE: 4.0 | # QB: 3
EPS current Quarter (2026-09-30): EPS=-1.18 | Chg30d=+3.63% | Revisions=+25% | Analysts=12
EPS current Year (2026-12-31): EPS=-4.62 | Chg30d=+3.48% | Revisions=+0% | GrowthEPS=+6.7% | GrowthRev=+664.2%
EPS next Year (2027-12-31): EPS=-4.07 | Chg30d=+3.28% | Revisions=+40% | GrowthEPS=+11.8% | GrowthRev=+192.8%
[Analyst] Revisions Ratio: +38% (up=4, down=1)